Evidence map›Paper›PMID 28587819›Full record

ArticleBehavioural brain research2017

Prodepressant- and anxiogenic-like effects of serotonin-selective, but not noradrenaline-selective, antidepressant agents in mice lacking α2-containing GABA

Rebecca S Benham, Nishani B Hewage, Raymond F Suckow, Elif Engin, Uwe Rudolph

Erratum issuedAbstract read
In one paragraph

Article in Behavioural brain research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.3field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. α2-containing γ-aminobutyric acid type A receptors promote stress resiliency in male mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Article
  7. Review
  8. Article
  9. An Emerging Circuit Pharmacology of GABATrends in pharmacological sciences · 2018
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Rebecca S BenhamLaboratory of Genetic Neuropharmacology, McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA; Department of Psychiatry, Harvard Medical School, 401 Park Drive, Boston, MA, 02215, USA. Electronic address: rbenhamvautour@mclean.harvard.edu.
Nishani B HewageLaboratory of Genetic Neuropharmacology, McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA; Department of Psychiatry, Harvard Medical School, 401 Park Drive, Boston, MA, 02215, USA. Electronic address: nishani.hewage@tufts.edu.
Raymond F SuckowAnalytical Psychopharmacology Laboratory, New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA. Electronic address: Suckow@NKI.rfmh.org.
Elif EnginLaboratory of Genetic Neuropharmacology, McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA; Department of Psychiatry, Harvard Medical School, 401 Park Drive, Boston, MA, 02215, USA. Electronic address: eengin@mclean.harvard.edu.
Uwe RudolphLaboratory of Genetic Neuropharmacology, McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA; Department of Psychiatry, Harvard Medical School, 401 Park Drive, Boston, MA, 02215, USA. Electronic address: urudolph@mclean.harvard.edu.
Harvard University · USMcLean Hospital · USNew York State Psychiatric Institute

Funding

A GABA Pathway to Faster Acting AntidepressantsR01MH095905 · NIMH · MCLEAN HOSPITAL · PI RUDOLPH, UWE · 2012 to 2016
$2.0M
NIMH NIH HHS R01 MH095905
6 · The paper itself

Abstract

Deficits in neuronal inhibition via gamma-aminobutyric acid (GABA) type A receptors (GABAA-Rs) are implicated in the pathophysiology of major depressive disorder and the therapeutic effects of current antidepressant treatments, however, the relevant GABAA-R subtype as defined by its alpha subunit is still unknown. We previously reported anxiety- and depressive-like behavior in alpha2+/- and alpha2-/- mice, respectively (Vollenweider, 2011). We sought to determine whether this phenotype could be reversed by chronic antidepressant treatment. Adult male mice received 4 or 8mg/kg fluoxetine or 53mg/kg desipramine in their drinking water for four weeks before undergoing behavioral testing. In the novelty suppressed feeding test, desipramine had anxiolytic-like effects reducing the latencies to bite and to eat the pellet in both wild-type and alpha2+/- mice. Surprisingly, 4mg/kg fluoxetine had anxiogenic-like effects in alpha2+/- mice increasing latency to bite and to eat while 8mg/kg fluoxetine increased the latency to eat in both wild-type and alpha2+/- mice. In the forced swim and tail suspension tests, chronic desipramine treatment increased latency to immobility in wild-type and alpha2-/- mice. In contrast, chronic fluoxetine treatment increased immobility in alpha2-/- mice in both tasks while generally having no effect in wild-type mice. These findings suggest that in preclinical paradigms of anxiety and behavioral despair the antidepressant-like effects of desipramine are independent of alpha2-containing GABAA-Rs, while a reduction in alpha2 expression leads to an increased sensitivity to anxiogenic- and prodepressant-like effects with chronic fluoxetine treatment, pointing to a potential role of alpha2-containing GABAA-Rs in the response to serotonin-selective antidepressants.

Indexed as

Adrenergic Uptake InhibitorsAnimalsAntidepressive AgentsAnxietyDepressionDesipramineDose-Response Relationship, DrugFeeding BehaviorFluoxetineMaleMice, 129 StrainMice, KnockoutMotor ActivityPhenotypeReceptors, GABA-ASelective Serotonin Reuptake InhibitorsAdrenergic Uptake InhibitorsAntidepressive AgentsDesipramineFluoxetineGabra2 protein, mousenorfluoxetineReceptors, GABA-ASelective Serotonin Reuptake InhibitorsAnxietyBehavioral despairDesipramineFluoxetineGabra2

Identifiers

PMID28587819
PMCPMC5551052
OpenAlexW2620958995

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.